Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
J Mol Cell Cardiol ; 130: 184-196, 2019 05.
Article in English | MEDLINE | ID: mdl-30986378

ABSTRACT

Maladaptive hypertrophy of cardiac myocytes increases the risk of heart failure. The underlying signaling can be triggered and interrogated in cultured neonatal ventricular myocytes (NRVMs) using sophisticated pharmacological and genetic techniques. However, the methods for quantifying cell growth are, by comparison, inadequate. The lack of quantitative, calibratable and computationally-inexpensive high-throughput technology has limited the scope for using cultured myocytes in large-scale analyses. We present a ratiometric method for quantifying the hypertrophic growth of cultured myocytes, compatible with high-throughput imaging platforms. Protein biomass was assayed from sulforhodamine B (SRB) fluorescence, and image analysis calculated the quotient of signal from extra-nuclear and nuclear regions. The former readout relates to hypertrophic growth, whereas the latter is a reference for correcting protein-independent (e.g. equipment-related) variables. This ratiometric measure, when normalized to the number of cells, provides a robust quantification of cellular hypertrophy. The method was tested by comparing the efficacy of various chemical agonists to evoke hypertrophy, and verified using independent assays (myocyte area, transcripts of markers). The method's high resolving power and wide dynamic range were confirmed by the ability to generate concentration-response curves, track the time-course of hypertrophic responses with fine temporal resolution, describe drug/agonist interactions, and screen for novel anti-hypertrophic agents. The method can be implemented as an end-point in protocols investigating hypertrophy, and is compatible with automated plate-reader platforms for generating high-throughput data, thereby reducing investigator-bias. Finally, the computationally-minimal workflow required for obtaining measurements makes the method simple to implement in most laboratories.


Subject(s)
Cardiomegaly , Image Processing, Computer-Assisted , Myocytes, Cardiac , Rhodamines/chemistry , Animals , Cardiomegaly/metabolism , Cardiomegaly/pathology , Cells, Cultured , Microscopy, Fluorescence , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology , Rats , Rats, Sprague-Dawley
2.
Oncotarget ; 7(28): 43997-44012, 2016 Jul 12.
Article in English | MEDLINE | ID: mdl-27259267

ABSTRACT

Gastric cancer is one of the most common malignancies and a leading cause of cancer death worldwide. The prognosis of stomach cancer is generally poor as this cancer is not very sensitive to commonly used chemotherapies. Epigenetic modifications play a key role in gastric cancer and contribute to the development and progression of this malignancy. In order to explore new treatment options in this target area we have screened a library of epigenetic inhibitors against gastric cancer cell lines and identified inhibitors for the BET family of bromodomains as potent inhibitors of gastric cancer cell proliferations. Here we show that both the pan-BET inhibitor (+)-JQ1 as well as a newly developed specific isoxazole inhibitor, PNZ5, showed potent inhibition of gastric cancer cell growth. Intriguingly, we found differences in the antiproliferative response between gastric cancer cells tested derived from Brazilian patients as compared to those from Asian patients, the latter being largely resistant to BET inhibition. As BET inhibitors are entering clinical trials these findings provide the first starting point for future therapies targeting gastric cancer.


Subject(s)
Azepines/pharmacology , Cell Proliferation/drug effects , Isoxazoles/pharmacology , Nuclear Proteins/antagonists & inhibitors , Transcription Factors/antagonists & inhibitors , Triazoles/pharmacology , Apoptosis/drug effects , Apoptosis/genetics , Asian People , Azepines/chemistry , Brazil , Cell Cycle Proteins , Cell Line, Tumor , Cell Proliferation/genetics , Gene Expression Profiling , HEK293 Cells , Humans , Isoxazoles/chemistry , Molecular Structure , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Proto-Oncogene Proteins c-myc/genetics , Proto-Oncogene Proteins c-myc/metabolism , Spheroids, Cellular/drug effects , Spheroids, Cellular/metabolism , Stomach Neoplasms/ethnology , Stomach Neoplasms/genetics , Stomach Neoplasms/metabolism , Transcription Factors/genetics , Transcription Factors/metabolism , Triazoles/chemistry
3.
J Med Chem ; 59(4): 1642-7, 2016 Feb 25.
Article in English | MEDLINE | ID: mdl-25974391

ABSTRACT

TRIM24 is a transcriptional regulator as well as an E3 ubiquitin ligase. It is overexpressed in diverse tumors, and high expression levels have been linked to poor prognosis in breast cancer patients. TRIM24 contains a PHD/bromodomain offering the opportunity to develop protein interaction inhibitors that target this protein interaction module. Here we identified potent acetyl-lysine mimetic benzimidazolones TRIM24 bromodomain inhibitors. The best compound of this series is a selective BRPF1B/TRIM24 dual inhibitor that bound with a KD of 137 and 222 nM, respectively, but exerted good selectivity over other bromodomains. Cellular activity of the inhibitor was demonstrated using FRAP assays as well as cell viability data.


Subject(s)
Adaptor Proteins, Signal Transducing/antagonists & inhibitors , Benzimidazoles/chemistry , Benzimidazoles/pharmacology , Carrier Proteins/antagonists & inhibitors , Nuclear Proteins/antagonists & inhibitors , Adaptor Proteins, Signal Transducing/chemistry , Adaptor Proteins, Signal Transducing/metabolism , Carrier Proteins/chemistry , Carrier Proteins/metabolism , Cell Line, Tumor , Crystallography, X-Ray , DNA-Binding Proteins , Humans , Lysine/analogs & derivatives , Models, Molecular , Molecular Docking Simulation , Nuclear Proteins/chemistry , Nuclear Proteins/metabolism , Protein Structure, Tertiary/drug effects
4.
Hum Gene Ther Clin Dev ; 25(2): 97-107, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24865497

ABSTRACT

Abstract Lung gene therapy is being evaluated for a range of acute and chronic diseases, including cystic fibrosis (CF). As these therapies approach clinical realization, it is becoming increasingly clear that the ability to efficiently deliver gene transfer agents (GTAs) to target cell populations within the lung may prove just as critical as the gene therapy formulation itself in terms of generating positive clinical outcomes. Key to the success of any aerosol gene therapy is the interaction between the GTA and nebulization device. We evaluated the effects of aerosolization on our preferred formulation, plasmid DNA (pDNA) complexed with the cationic liposome GL67A (pDNA/GL67A) using commercially available nebulizer devices. The relatively high viscosity (6.3±0.1 cP) and particulate nature of pDNA/GL67A formulations hindered stable aerosol generation in ultrasonic and vibrating mesh nebulizers but was not problematic in the jet nebulizers tested. Aerosol size characteristics varied significantly between devices, but the AeroEclipse II nebulizer operating at 50 psi generated stable pDNA/GL67A aerosols suitable for delivery to the CF lung (mass median aerodynamic diameter 3.4±0.1 µm). Importantly, biological function of pDNA/GL67A formulations was retained after nebulization, and although aerosol delivery rate was lower than that of other devices (0.17±0.01 ml/min), the breath-actuated AeroEclipse II nebulizer generated aerosol only during the inspiratory phase and as such was more efficient than other devices with 83±3% of generated aerosol available for patient inhalation. On the basis of these results, we have selected the AeroEclipse II nebulizer for the delivery of pDNA/GL67A formulations to the lungs of CF patients as part of phase IIa/b clinical studies.


Subject(s)
Aerosols/chemistry , Cystic Fibrosis/therapy , DNA/metabolism , Liposomes/chemistry , Lung/metabolism , Administration, Inhalation , Animals , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , DNA/chemistry , Female , Genetic Therapy , Mice , Mice, Inbred BALB C , Nebulizers and Vaporizers , Plasmids/genetics , Plasmids/metabolism
5.
J Mol Med (Berl) ; 90(12): 1487-96, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22767241

ABSTRACT

Transcriptional control of transgene expression is crucial to successful gene therapy, yet few promoter/enhancer combinations have been tested in clinical trials. We created a simple, desktop computer database and populated it with promoter sequences from publicly available sources. From this database, we rapidly identified novel CpG-free promoter sequences suitable for use in non-inflammatory, non-viral in vivo gene transfer. In a simple model of lung gene transfer, five of the six promoter elements selected, chosen without prior knowledge of their transcriptional activities, directed significant transgene expression. Each of the five novel promoters directed transgene expression for at least 14 days post-delivery, greatly exceeding the duration achieved with the commonly used CpG-rich viral enhancer/promoters. Novel promoter activity was also evaluated in a more clinically relevant model of aerosol-mediated lung gene transfer and in the liver following delivery via high-pressure tail vein injection. In each case, the novel CpG-free promoters exhibited higher and/or more sustained transgene expression than commonly used CpG-rich enhancer/promoter sequences. This study demonstrates that novel CpG-free promoters can be readily identified and that they can direct significant levels of transgene expression. Furthermore, the database search criteria can be quickly adjusted to identify other novel promoter elements for a variety of transgene expression applications.


Subject(s)
Genetic Therapy/methods , Promoter Regions, Genetic/genetics , Genetic Vectors/genetics , Transgenes/genetics
6.
Biomaterials ; 33(28): 6833-42, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22727465

ABSTRACT

Clinical studies are underway for the aerosol delivery of plasmid DNA complexed with Genzyme Lipid GL67A to the lungs of patients with cystic fibrosis (CF). Plasmid vectors contain several functional elements all of which play a role in determining the efficacy of the final clinical product. To optimise the final plasmid, variations of CpG-free 5' enhancer elements and 3'UTR regions were inserted into a common CpG-free, plasmid backbone containing Luciferase or CFTR transgenes. Plasmids were compared in immortalised cell culture, human airway liquid interface primary cell cultures, and mouse lung models to determine which design directed optimal transgene expression. Following aerosol delivery to mouse lung, plasmids containing the murine CMV enhancer showed higher peak Luciferase activity than the human CMV enhancer, but the human version resulted in persistent expression. In cell culture, the SV40 3'UTR and a novel BGH2 3'UTR exhibited up to 20-fold higher Luciferase activity than the commonly used BGH 3'UTR, but in mouse lung aerosol studies the activity and duration was greater for BGH 3'UTR. Systematic evaluation of each functional component of the plasmid has resulted in an improved design, exhibiting superior levels and duration of lung gene expression.


Subject(s)
Cystic Fibrosis/therapy , Enhancer Elements, Genetic , Gene Transfer Techniques , Genetic Therapy/methods , Plasmids/genetics , Promoter Regions, Genetic , Aerosols/chemistry , Animals , CpG Islands/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/administration & dosage , Cystic Fibrosis Transmembrane Conductance Regulator/chemistry , DNA/administration & dosage , Female , Gene Expression/genetics , HEK293 Cells , Humans , Luciferases/administration & dosage , Luciferases/chemistry , Lung/metabolism , Mice , Mice, Inbred BALB C , Plasmids/administration & dosage , Transgenes
7.
Biomaterials ; 33(22): 5618-27, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22575838

ABSTRACT

Aerosol gene therapy offers great potential for treating acquired and inherited lung diseases. For treatment of chronic lung diseases such as cystic fibrosis, asthma and emphysema, non-viral gene therapy will likely require repeated administration to maintain transgene expression in slowly dividing, or terminally differentiated, lung epithelial cells. When complexed with plasmid DNA (pDNA), the synthetic polymer, 25 kDa branched Polyethylenimine (PEI), can be formulated for aerosol delivery to the lungs. We show that pDNA/PEI aerosol formulations can be repeatedly administered to airways of mice on at least 10 occasions with no detectable toxicity. Interestingly, peak reporter gene activity upon repeated delivery was significantly reduced by up to 75% compared with a single administration, despite similar pDNA lung deposition at each subsequent aerosol exposure. Although the precise mechanism of inhibition is unknown, it is independent of mouse strain, does not involve an immune response, and is mediated by PEI. Importantly, using a dosing interval of 56 days, delivery of a fourth-generation, CpG-free plasmid generated high-level, sustained transgene expression, which was further boosted at subsequent administrations. Together these data indicate that pDNA/PEI aerosol formulations offer a versatile platform for gene delivery to the lung resulting in sustained transgene expression suitable for treatment of chronic lung diseases.


Subject(s)
CpG Islands/genetics , Drug Carriers/chemistry , Gene Expression Regulation/genetics , Imines/chemistry , Lung/physiology , Plasmids/administration & dosage , Plasmids/genetics , Polyethylenes/chemistry , Administration, Inhalation , Aerosols/administration & dosage , Animals , Female , Gene Expression Regulation/drug effects , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Tissue Distribution
8.
Biotechniques ; 49(3): 666-8, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20854270

ABSTRACT

Nonviral gene therapy utilizing plasmid DNA (pDNA) complexed with cationic lipids (lipoplexes) or cationic polymers (polyplexes) has demonstrated considerable potential for the treatment of a variety of diseases. However, progress toward clinical application is often delayed by the lack of reliable and scalable mixing of components sufficient to guarantee consistent performance in vivo. Attempts to improve and standardize mixing have been limited by the sensitivity of pDNA to shear-related degradation. Here we describe a simple pneumatic mixing device that enables the rapid and reproducible production of large volumes of nonviral gene therapy formulations and demonstrate its suitability for use with shear-sensitive pDNA.


Subject(s)
DNA/administration & dosage , Genetic Therapy/instrumentation , Plasmids/administration & dosage , Animals , Cations/chemistry , DNA/chemistry , DNA/genetics , Equipment Design , Gene Expression , Lipids/chemistry , Mice , Mice, Inbred BALB C , Plasmids/chemistry , Plasmids/genetics
9.
Mol Ther ; 16(5): 812-8, 2008 May.
Article in English | MEDLINE | ID: mdl-18388934

ABSTRACT

Gene therapy is being investigated in the treatment of lung-related aspects of the genetic disease, Cystic fibrosis (CF). Clinical studies have demonstrated CF transmembrane conductance regulator (CFTR) expression in the airways of adults with CF using a variety of gene transfer agents. In utero gene therapy is an alternative approach that facilitates vector transduction of rapidly expanding populations of target cells while avoiding immune recognition of the vector. In CF, in utero gene transfer could potentially delay the onset of disease symptoms in childhood and compensate for the role, if any, that CFTR plays in the developing organs. Previously published studies have suggested that transient expression of CFTR in utero was sufficient to rescue the fatal intestinal defect in S489X Cftr(tm1Unc)/Cftr(tm1Unc) knockout mice. We replicated these studies using an identical CFTR-expressing adenoviral vector and CF mouse strain in sufficiently large numbers to provide robust Kaplan-Meier survival data. Although each step of the procedure was carefully controlled and vector-specific CFTR expression was confirmed in the fetal organs after treatment, there was statistically no significant improvement in the survival of mice treated in utero with AdCFTR, compared with contemporaneous control animals.


Subject(s)
Adenoviridae/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/genetics , Cystic Fibrosis/therapy , Gene Expression Regulation , Genetic Therapy/methods , Amniotic Fluid/metabolism , Animals , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Female , Genetic Vectors , Humans , Mice , Mice, Inbred C57BL , Mice, Knockout , Pregnancy , Pregnancy, Animal
10.
Nat Biotechnol ; 26(5): 549-51, 2008 May.
Article in English | MEDLINE | ID: mdl-18438402

ABSTRACT

Pulmonary delivery of plasmid DNA (pDNA)/cationic liposome complexes is associated with an acute unmethylated CG dinucleotide (CpG)-mediated inflammatory response and brief duration of transgene expression. We demonstrate that retention of even a single CpG in pDNA is sufficient to elicit an inflammatory response, whereas CpG-free pDNA vectors do not. Using a CpG-free pDNA expression vector, we achieved sustained (>or=56 d) in vivo transgene expression in the absence of lung inflammation.


Subject(s)
CpG Islands/genetics , Gene Targeting/methods , Genetic Therapy/methods , Inflammation/genetics , Inflammation/prevention & control , Lung/metabolism , Plasmids/genetics , Plasmids/therapeutic use , Animals
SELECTION OF CITATIONS
SEARCH DETAIL
...